Clinical Trials Logo

Cancer of Stomach clinical trials

View clinical trials related to Cancer of Stomach.

Filter by:

NCT ID: NCT05804331 Recruiting - Gastric Cancer Clinical Trials

The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study

ANZ UGI
Start date: March 14, 2023
Phase:
Study type: Observational [Patient Registry]

To determine the long term outcomes of Endoscopic Submucosal Dissection (ESD), Endoscopic Full Thickness Resection (EFTR) and Submucosal-Tunnelling Endoscopic Resection (STER) for upper gastrointestinal neoplastic lesions

NCT ID: NCT05747482 Not yet recruiting - Cancer of Stomach Clinical Trials

Omentectomy vs Omental Preservation in Resectable Cancer

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

European clinical guidelines do not establish a clear recommendation neither for nor against omentectomy of this segment, the American clinical guidelines recommend omentectomy in view of its potential long-term oncological benefit, and Japanese clinical guidelines only recommend 2nd segment omentectomy in locally advanced gastric cancers (stage T3-T4) recommending omental preservation in early gastric cancers (stage T1-T2). Faced with this lack of consensus, we propose a randomized, prospective and multicentric study in patients with resectable gastric cancer in stage T3-4 N+/- M0. Patients will be randomized into two groups, one where omentectomy of the 2nd omental portion will be performed and another where omental preservation will be performed. The aim of our study is to analyze the disease-free interval and survival between both groups, also comparing postoperative complications and mortality.

NCT ID: NCT05688761 Completed - Drug Use Clinical Trials

Nordic Gastric and Esophageal Tumor Study

NordGETS
Start date: January 1, 2019
Phase:
Study type: Observational [Patient Registry]

This is a population-based case-control study in all 5 Nordic countries from 1994 onwards. All cases with an esophageal or gastric tumor will be compared with 10 times as many population controls, frequency-matched by age, sex, and calendar year, country. This design offers excellent statistical power, length and completeness of follow-up, quality of data on exposures, outcomes and confounders, and control for confounding. The project will include a specific study entitled "Long-term medication with proton pump inhibitors and risk of gastric cancer", which is summarized here: Research question: Medication with proton pump inhibitors (PPI) (e.g., omeprazole and esomeprazole) is one of the most common long-term therapies globally, prompted by its high anti-acidic efficacy and good short-term safety profile. Gastric cancer is the 3rd leading cause of cancer-related mortality globally, responsible for 770,000 deaths each year. There are clear biological mechanisms linking long-term PPI-use with an increased risk of gastric cancer. However, existing research has not been able to provide a definite answer to whether long-term PPI-use is associated with an increased risk of gastric cancer. The reasons are that the literature is hampered by too short follow-up time to assess cancer development, and also insufficient statistical power, lack of population-based design and confounding. With the availability of nationwide complete medication registries in the Nordic countries, the firsts two starting already in 1994 (Denmark and Finland), we can now, by adding registry data from all Nordic countries together, conduct the first study providing a robust and valid answer to this research question. Overarching aim This project aims to clarify if (and if so to what extent) long-term PPI-therapy influences the risk of developing gastric adenocarcinoma. For validation reasons, we will also examine how long-term use of histamine-2-receptor blockers (H2RB) influences the risk of developing gastric adenocarcinoma. These analyses will validate that the findings are specific for PPIs. H2RB are used for the same indications as PPIs, but with a different biological mechanism. Hypothesis We plan to test the hypothesis that long-term use of PPI (but not H2RB) increases the risk of gastric adenocarcinoma. Prerequisites This will be the first project with all prerequisites to provide conclusive answers to the hypotheses above, i.e.: - Long follow-up (up to 28 years) - Complete follow-up (by virtue of the nationwide complete Nordic registries) - Population-based design (which rules out biased selection of cases or controls) - Superior statistical power (all five Nordic countries participate with nationwide data) - High-quality data on exposures, outcomes and confounders (thanks to well-maintained and complete nationwide Nordic health data registries) - Control for confounding factors (available for all participants, both cases and controls)

NCT ID: NCT05311176 Active, not recruiting - Gastric Cancer Clinical Trials

A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)

nextHERIZON
Start date: August 17, 2022
Phase: Phase 2
Study type: Interventional

This is a Phase 2, signal generating, open-label, 2-Arm, non-randomized study, in patients with metastatic HER2/neu over-expressing gastric cancer or gastroesophageal adenocarcinomas.

NCT ID: NCT05179824 Recruiting - Breast Cancer Clinical Trials

Tempus Priority Study: A Pan-tumor Observational Study

Start date: October 19, 2020
Phase:
Study type: Observational

Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with the goal of conducting research to advance cancer care and create a dataset that furthers cancer research.

NCT ID: NCT05088304 Completed - Malnutrition Clinical Trials

GLIM-defined Malnutrition Criteria for Postoperative Outcomes in Patients With Esophagogastric Cancer

Start date: September 1, 2015
Phase:
Study type: Observational

The present study aims to investigate the prognostic value of preoperative fat-free mass index for postoperative outcomes in patients undergoing esophagogastric cancer surgery, and to explore the role of the FFMI in the Global Leadership Initiative on Malnutrition (GLIM) criteria.

NCT ID: NCT05041335 Not yet recruiting - Cancer Clinical Trials

Wet Heparinized Suction for Abdominal Cancer

EUS Heparin
Start date: June 15, 2024
Phase: N/A
Study type: Interventional

The purpose of this research is to compare the amount and quality of tissue obtained by EUS-FNB when the device is flushed with an anticoagulant or "blood thinner" vs. saline a salt water solution as well as the use of a microsieve in order for the doctor to look at the tissue to check the acceptability of the specimens before sending for analysis. You will be randomly assigned (like a flip of a coin) to have either the blood thinner or the salt water solution placed within the needle being used to sample your abdominal tumor and to have either a sieve used or not. You will be one of 42 participants enrolled in this data collection study which includes 1 sites in the United States.

NCT ID: NCT04270890 Recruiting - Cancer, Lung Clinical Trials

Investigation of an Abdominal Compression Device

ACE02
Start date: June 21, 2018
Phase: N/A
Study type: Interventional

This study is applicable to patients undergoing lower lung or abdomen stereotactic ablative body radiotherapy (SABR) treatment. The purpose of the ACE 01 study is to identify if, the volume of healthy tissue within the treatment area and therefore subsequent side effects, can be reduced by using a commercially available abdominal compression device to minimise breathing related movement. The secondary aim will be to assess patient compliance and comfort of thedevice. This will be assessed by asking the patient to complete a 'patient comfort questionnaire'. In addition the radiographers will be asked to complete a 'satisfaction questionnaire' to determine ease and reproducibility of use.

NCT ID: NCT04032353 Recruiting - Cancer of Stomach Clinical Trials

Medical Consortium for Screening Upper Gastrointestinal Cancers With Magnetically Controlled Capsule Gastroscopy

Start date: December 31, 2018
Phase: N/A
Study type: Interventional

The aim of our study was to demonstrate the efficacy and feasibility of the medical consortium for screening upper gastrointestinal cancers with magnetically controlled capsule gastroscopy.

NCT ID: NCT03949907 Recruiting - Clinical trials for GastroEsophageal Cancer

Early IntraVenous Administration of Nutritional Support

IVANS
Start date: April 14, 2020
Phase: N/A
Study type: Interventional

The present trial will be conducted to verify if early supplemental parenteral nutrition in combination with nutritional counseling improves survival and the feasibility of chemotherapy, in addition to nutritional status, body composition, functional status and quality of life in treatment-naïve patients with metastatic gastric cancer at nutritional risk undergoing first-line chemotherapy.